Abiraterone Acetate - Zytiga

On April 28, 2011, the US Food and Drug Administration (FDA) approved Zytiga (abiraterone acetate), for use in combination with prednisone for the second-line treatment of castration-resistant prost...

What is new in prostate cancer research and development?

Key research areas in relation to Prostate Cancer are discussed below.  Brief descriptions are supported by hyperlinks to the most relevant research papers and current affairs news reports and...

Abiraterone Approval Extended to Treat Late-Stage Prostate Cancer

Men with castration-resistant prostate cancer that has spread can now be treated with abiraterone acetate (Zytiga) before receiving chemotherapy. The Food and Drug Administration (FDA) expanded the ap...

Data support abiraterone use first-line

Patients with advanced prostate cancer who have not received chemotherapy could be treated with abiraterone first line...

Abiraterone Blocks Chemo-Naïve Prostate Cancer

Radiographic progression-free survival was a median of 8.3 months in the control arm, but had not been reached in the abiraterone arm (HR, 0.43; P less than .0001).

Urological cancer: Abiraterone and its place in the treatment of metastatic CRPC

An update of the COU-AA-301 study confirms a survival advantage with abiraterone–prednisone compared to prednisone in post-docetaxel patients with metastatic castration-resistant prostate cancer. We...

Abiraterone has been accepted for restricted use in NHS Scotland

In its latest round of appraisals (July 2012), the Scottish Medicines Consortium approved NHS funding of abiraterone if it is provided...

Abiraterone available across the UK… finally!

We’re delighted with today’s news that abiraterone will be available for men with advanced prostate cancer on the NHS in Scotland. This is fantastic for Scottish men with the disease as it brings...

Abiraterone improves outcomes for prostate cancer prior to chemo

Treatment with abiraterone acetate, an androgen biosynthesis inhibitor, may benefit patients with progressive metastatic castration-resistant prostate cancer who have not yet undergone chemotherapy, r...

[Comment] Abiraterone acetate for metastatic prostate cancer

In The Lancet Oncology, Karim Fizazi and colleagues update the landmark COU-AA-301 trial, which assessed abiraterone acetate, an inhibitor of CYP17 that suppresses androgen synthesis, for men with pro...

Abiraterone acetate: in metastatic castration-resistant prostate cancer.

Oral abiraterone acetate, in combination with prednisone/prednisolone, is used to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-cont...

Results of the Medicare Health Support disease-management pilot program.

In the Medicare Modernization Act of 2003, Congress required the Centers for Medicare and Medicaid Services to test the commercial disease-management model in the Medicare fee-for-service program.

Abiraterone and Increased Survival in Metastatic Prostate Cancer.

To the Editor: De Bono et al. (May 26 issue)(1) report that the CYP17 inhibitor abiraterone increased survival in patients with metastatic castration-resistant prostate cancer. However, CYP17 inhibiti...

Abiraterone and Increased Survival in Metastatic Prostate Cancer.

To the Editor: De Bono et al. (May 26 issue)(1) report that the CYP17 inhibitor abiraterone increased survival in patients with metastatic castration-resistant prostate cancer. However, CYP17 inhibiti...

Abiraterone and Increased Survival in Metastatic Prostate Cancer.

To the Editor: De Bono et al. (May 26 issue)(1) report that the CYP17 inhibitor abiraterone increased survival in patients with metastatic castration-resistant prostate cancer. However, CYP17 inhibiti...